Enhanced Severe Acute Respiratory Syndrome Coronavirus 2 Antigen-Specific Systemic Immune Responses in Multisystem Inflammatory Syndrome in Children and Reversal After Recovery.
dc.contributor.author | Kumar, NP | en_US |
dc.contributor.author | Venkataraman, A | en_US |
dc.contributor.author | Nancy, A | en_US |
dc.contributor.author | Moideen, K | en_US |
dc.contributor.author | Varadarjan, P | en_US |
dc.contributor.author | Selladurai, E | en_US |
dc.contributor.author | Sangaralingam, T | en_US |
dc.contributor.author | Selvam, R | en_US |
dc.contributor.author | Thimmaiah, A | en_US |
dc.contributor.author | Natarajan, S | en_US |
dc.contributor.author | Ramasamy, G | en_US |
dc.contributor.author | Hissar, S | en_US |
dc.contributor.author | Radayam Ranganathan, U | en_US |
dc.contributor.author | Babu, S | en_US |
dc.date.accessioned | 2023-01-03T16:39:24Z | |
dc.date.issued | 2022-09-28 | en_US |
dc.identifier.uri | https://qmro.qmul.ac.uk/xmlui/handle/123456789/83373 | |
dc.description.abstract | BACKGROUND: Multisystem inflammatory syndrome in children (MIS-C) presents with inflammation and pathology of multiple organs in the pediatric population in the weeks following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. METHODS: We characterized the SARS-CoV-2 antigen-specific cytokine and chemokine responses in children with MIS-C, coronavirus disease 2019 (COVID-19), and other infectious diseases. RESULTS: MIS-C is characterized by elevated levels of type 1 (interferon-γ, interleukin [IL] 2), type 2 (IL-4, IL-13), type 17 (IL-17), and other proinflammatory cytokines (IL-1α, IL-6, IL-12p70, IL-18, and granulocyte-macrophage colony-stimulating factor) in comparison to COVID-19 and other infectious diseases following stimulation with SARS-CoV-2-specific antigens. Similarly, upon SARS-CoV-2 antigen stimulation, CCL2, CCL3, and CXCL10 chemokines were significantly elevated in children with MIS-C in comparison to the other 2 groups. Principal component analysis based on these cytokines and chemokines could clearly distinguish MIS-C from both COVID-19 and other infections. In addition, these responses were significantly diminished and normalized 6-9 months after recovery. CONCLUSIONS: Our data suggest that MIS-C is characterized by an enhanced production of cytokines and chemokines that may be associated with disease pathogenesis. | en_US |
dc.format.extent | 1215 - 1223 | en_US |
dc.language | eng | en_US |
dc.relation.ispartof | J Infect Dis | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | MIS-C | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | chemokines | en_US |
dc.subject | cytokines | en_US |
dc.subject | in vitro cell culture | en_US |
dc.subject | pediatric population | en_US |
dc.subject | Antigens, Viral | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Chemokines | en_US |
dc.subject | Child | en_US |
dc.subject | Communicable Diseases | en_US |
dc.subject | Cytokines | en_US |
dc.subject | Granulocyte-Macrophage Colony-Stimulating Factor | en_US |
dc.subject | Humans | en_US |
dc.subject | Immunity | en_US |
dc.subject | Interferon-gamma | en_US |
dc.subject | Interleukin-13 | en_US |
dc.subject | Interleukin-17 | en_US |
dc.subject | Interleukin-18 | en_US |
dc.subject | Interleukin-4 | en_US |
dc.subject | Interleukin-6 | en_US |
dc.subject | SARS-CoV-2 | en_US |
dc.subject | Systemic Inflammatory Response Syndrome | en_US |
dc.title | Enhanced Severe Acute Respiratory Syndrome Coronavirus 2 Antigen-Specific Systemic Immune Responses in Multisystem Inflammatory Syndrome in Children and Reversal After Recovery. | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1093/infdis/jiac304 | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35932220 | en_US |
pubs.issue | 7 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 226 | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Centre for Immunobiology [1121]